ClinicalTrials.gg
RecruitingNCT06398847Updated Jul 27, 2026

Virtual Reality (VR) Self-Hypnosis Software

An interventional study of Virtual Reality headset in Musculoskeletal Pain, Neuropathic Pain and Neuralgia, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 155 studies in Musculoskeletal Pain with a site in United States — 29 open to participants now, 35 under way, 1 of them phase 3. Musculoskeletal Pain · United States.

Planned enrollment
87th of 136
40 · median 60
Started
2026
with 17 others
No phase
114 of 155
22 open now
Primary completion
2027-06
later than 16 of 34 live
Registered
116th of 155
by date

Among the 155 studies in Musculoskeletal Pain with a site in United States, this one is the 87th largest by planned enrollment of the 136 interventional ones that give a count, is one of 18 that started in 2026, is one of 114 with no phase, reaches primary completion later than 16 of the 34 other live ones, and was the 116th registered.

Musculoskeletal Pain

518 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.

Browse Musculoskeletal Pain studies →

Open to participants now

29 of the 155 studies in Musculoskeletal Pain with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Musculoskeletal Pain studies recruiting now, 30 (45%) set no upper age limit and 30 (45%) stop at 75 or younger; 8 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Musculoskeletal Pain with a site in United States, or all of them as a file.
02

Study summary

This single-site study of self-hypnosis software using an off-the-shelf virtual reality (VR) device (OculusGo™) to determine the software's safety, usability, and preliminary efficacy in pain relief for HIV-associated chronic pain patients. This is funded under the i Prism Funding through Mount Sinai Innovations.

Read the detailed description

The study will be done in two phases - Phase A is the development of the software by the study team and the engineers targeted to be completed by 4/15/2024. Testing will occur with only the study team. No participants will be involved in the testing phase. Phase B is the participant enrollment phase targeted to start 5/20/2024. A request for FDA Exemption of a non-significant risk combination device has been submitted and granted.

03

Conditions studied

  • Musculoskeletal Pain
  • Neuropathic Pain
  • Neuralgia

Keywords

  • HIV chronic pain
  • Self-hypnosis
  • virtual reality software
  • non-drug treatment for chronic pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Patient Eligibility

Inclusion criteria

Inclusion Criteria:

  • Adults age ≥18
  • Confirmed diagnosis of , currently on a stable antiretroviral regimen ≥ 90 days.
  • Documentation of chronic pain associated with HIV for≥90 days
  • Stable pain management regimen ≥90 days, or no pain treatments ≥90 days
  • Average pain intensity of 3 or greater on the NRS of the mean daily scores reported between Visit 1 and Visit 2
  • Access to the internet via smartphone, computer, or tablet 7. Fluent in English
  • Capable of giving and willingness to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • A co-occurring medical or psychiatric condition which would make participation in the study or complicate measurement of changes associated with the intervention.
  • Concurrent participation in another protocol for pain treatment
  • A psychiatric disorder, medical condition, or other life circumstance, which in the opinion of the PI, would contraindicate attendance at sessions, or make it unlikely that the participant could successfully complete the study procedures.
  • Current or prior diagnosis of epilepsy, seizure disorder, dementia, migraines, or other neurological conditions contraindicating the use of virtual reality devices.
  • A medical condition predisposing prospective participant to nausea or dizziness 6. Lack of stereoscopic vision or severe hearing impairment
  • Injury to eyes, face, or neck that impedes using the VR device
  • If participant has access to personal VR gear for gaming or other purposes at home, participant fails to agree not to use these personal VR gear during the course of the protocol.
  • Currently pregnant or planning to become pregnant during the study period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    HIV-associated Chronic Pain Patients

    The participants will be enrolled into an open label arm to determine feasibility and useability of the combination device.

    Device: Virtual Reality headset

Interventions

  • DeviceVirtual Reality headset

    Self-hypnosis software in a Virtual Reality headset. This is the development of software that provides a self-hypnosis experience that can be inserted into any virtual reality device.

    Also known as: OculusGo™

06

What researchers measure

Primary outcomes

  1. Number of times the software is used

    Feasibility of self-hypnosis software using VR devices as measured by frequency of use. The device software will have an ability to determine the number of times each participant used the self-hypnosis software during the 21-day period.

    Time frame: twenty one days

  2. Number of adverse events related to the device

    Safety will be measured by any adverse events related to the use of the software and the device.

    Time frame: twenty one days

Secondary outcomes

  1. Quality of Life measured using Pain, Enjoyment and General Activity Scale (PEG)

    Participants perception of pain and quality of life will be measured using the Pain, Enjoyment and General Activity Scale (PEG). The PEG (pain, enjoyment, general activity) composite score will be used to assess pain intensity and interference. The PEG is a 3-item score with potential responses of 0 to 10 with 10 being the most severe pain. The 3 PEG items referring to the past week are: average pain, how pain interfered with enjoyment of life, how pain interfered with general activity To compute the PEG score, add the responses to the questions above, then divide by three to get a final score out of 10, full scale ranges 0 (no pain) to 10 (most severe pain), with higher scores indicate higher levels of pain.

    Time frame: at Week 2, 3 and week 4

  2. Quality of life measured using Short Form Brief Pain Inventory (SF-BPI) Scale

    Participants perception of pain and quality of life will be measured using the Short Form Brief Pain Inventory (SF-BPI) Scale. BPI-SF is a 9-item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. This is a 10-point scale with 0 being the best possible score, meaning "no pain", and 10 being the worst possible score, meaning "pain as bad as you can imagine", thus, higher scores indicate worse health outcomes.

    Time frame: at Week 2, 3 and week 4

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Clinical study report

Time frame: Beginning 9 months and ending 36 months following article publication.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. To achieve aims in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in the University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be determined).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 226 non-industry interventional studies with no phase under Musculoskeletal Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's planned 15 months is above that.

Counting every sponsor, half of 239 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
May 3, 2024
StartActual
Mar 26, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06398847
Responsible party
Mary Catherine George (Director Clinical Research, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
May 3, 2024
Start date
Mar 26, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 27, 2026

Study contacts

Mary Catherine George, PhD
Contact
mary-catherine.george@mssm.edu
646-808-6231

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion